TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

The rebel leader who helped oust the Assad regime calls on countries to hand over “criminals” who fled Syria. A new caretaker prime minister warns that the country faces a dire financial ...

Christopher Wray Will Step Down as F.B.I. Director President-elect Trump had already signaled his intention to replace Mr. Wray with a longtime loyalist, Kash Patel. U.S. Colleges Warn Foreign ...

US Bankers Are Cautious Towards Cryptos Despite Upcoming Pro-Crypto Administration ...